GlassScriptPhysician profile
Katelyn Lee Conner
NPI 1760902712
$9,274.10
in general payments reported to CMS, 2019-2025
24 companies · $1,996 in 2025
The $1,996 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,304 · 2022: $2,281 · 2023: $1,944 · 2024: $1,748 · 2025: $1,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,649 · Education: $39.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,648.95 |
| Education | $39.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,376.61 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $896.03 | 2021-2025 | Caplyta |
| Alkermes, INC. | $766.19 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $740.21 | 2021-2024 | Jornay Pm |
| Lundbeck LLC | $587.48 | 2021-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $546.45 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $468.72 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $418.78 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $402.68 | 2022-2024 | Spravato, Invega, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $376.63 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $313.38 | 2022-2025 | Azstarys, Azstarys |
| Axsome Therapeutics, INC. | $262.79 | 2022-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $228.13 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $211.01 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $144.30 | 2021-2025 | Aplenzin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $108.29 | 2021-2023 | Belsomra |
| Teva Pharmaceuticals USA, INC. | $93.49 | 2021-2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $88.76 | 2022-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $86.84 | 2021-2022 | |
| Almatica Pharma LLC | $45.02 | 2021 | |
| Sunovion Pharmaceuticals INC. | $42.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2025 | Cobenfy |
| Novo Nordisk INC | $22.78 | 2023 | Wegovy |
| Eisai INC. | $19.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.